Trending Now
- “I will soon make an announcement regarding a statewide tour across Tamil Nadu.” – O. Panneerselvam.
- Vatsala, Asia’s oldest elephant, has passed away at Panna Tiger Reserve; social activists mourn the death of this elephant, which lived for over 100 years.
- “The U.S. Govt earned ₹8 lakh crore this year through increased tariffs on foreign goods.” – U.S President Donald Trump.
- World No.1 Aryna Sabalenka has advanced to the semifinals in the Women’s Singles category at Wimbledon Tennis.
Businesswire
SpeeDx announce a collaborative agreement with GSK to supply tests and technology
June 24, 2019
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has signed a collaborative agreement with GSK, to provide a combination of existing tests and custom test development to support certain GSK antibiotic clinical trials and new product development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190624005302/en/
“SpeeDx has a demonstrated commitment to improve patient care, and our tests currently used in clinical practice are supporting Resistance Guided Therapy, positively impacting cure rates and helping to minimise the spread of antimicrobial resistant infections.” Colin Denver, SpeeDx CEO. (Photo: Business Wire)
“We welcome this extension of the utility and application of our tests and technology,” said Colin Denver, SpeeDx CEO. “SpeeDx has a demonstrated commitment to improve patient care, and our tests currently used in clinical practice are supporting Resistance Guided Therapy, positively impacting cure rates and helping to minimise the spread of antimicrobial resistant infections.”
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information about SpeeDx please see: https://plexpcr.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190624005302/en/
Source: Businesswire
